SCHEMBL692754

SCHEMBL692754

Cc1ccc(S(=O)(=O)Nc2cccc(-c3ccc(NCc4ccccc4)nn3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
ALDH1A1 P00352 5/20 0.53
CYP1A2 P05177 3/20 0.53
CYP3A4 P08684 3/20 0.53
CYP2C19 P33261 3/20 0.53
HSD17B10 Q99714 2/20 0.53
CYP2D6 P10635 2/20 0.53
CLK4 Q9HAZ1 1/20 0.53
MAPT P10636 5/20 0.51
TP53 P04637 4/20 0.51
LMNA P02545 3/20 0.51
POLB P06746 1/20 0.51
RECQL P46063 1/20 0.50
THRB P10828 1/20 0.49
HPGD P15428 2/20 0.48
HTT P42858 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27899314 0.86 NPC1 (0.61) NPC1RAB9AALDH1A1MAPTTP53
SCHEMBL692541 0.79 NPC1 (0.53) NPC1RAB9AALDH1A1MAPTTP53
SCHEMBL19132170 0.72 PTPN2 (0.63) NPC1RAB9AALDH1A1MAPTTP53
SCHEMBL14877794 0.70 CA12 (0.76) ALDH1A1LMNAPOLBTHRBCA12
SCHEMBL8269562 0.70 TP53 (0.64) ALDH1A1MAPTTP53LMNACA12
SCHEMBL20444412 0.69 MEN1 (0.69) NPC1RAB9AALDH1A1MAPTLMNA
SCHEMBL27653427 0.69 HTR6 (0.76) ALDH1A1CA12CA1CA2CA9
SCHEMBL322990 0.69 CA12 (1.00) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL19119164 0.69 CA12 (1.00) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14125611 0.68 CA12 (0.63) ALDH1A1MAPTLMNAPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP claimed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US claimed
CN-102458122-A Compounds, compositions and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2012-05-16 CN claimed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP claimed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US claimed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO claimed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO claimed
CN-103068390-A Compounds, compositions, and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2013-04-24 CN disclosed
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
CN-102458122-A Compounds, compositions and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2012-05-16 CN disclosed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 NPC1 1061/4885RAB9A 2640/4885ALDH1A1 3140/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 NPC1 321/4885RAB9A 1696/4885ALDH1A1 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.